Literature DB >> 28723406

Systemic Therapy in Locally Advanced or Metastatic Adrenal Cancers: A Critical Appraisal and Clinical Trial Update.

Laura Ferrari1, Mélanie Claps1, Salvatore Grisanti1, Alfredo Berruti2.   

Abstract

Mitotane and chemotherapy with etoposide, doxorubicin, and cisplatin plus mitotane (EDP-M) are the only therapies with demonstrated efficacy in advanced adrenocortical carcinoma. Prognostic and predictive factors are needed to identify patients who could obtain the best benefit from these treatments. Despite the strong rationale for their use, clinical trials on molecular targeted therapies have failed to demonstrate that these drugs are efficacious in the management of this extremely rare disease.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Year:  2015        PMID: 28723406     DOI: 10.1016/j.euf.2015.06.005

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  5 in total

1.  Antineoplastic activity of artemisinin in adrenocortical carcinoma.

Authors:  Luigi Lorini; Salvatore Grisanti; Roberta Ambrosini; Deborah Cosentini; Marta Laganà; Luigi Grazioli; Guido A M Tiberio; Sandra Sigala; Alfredo Berruti
Journal:  Endocrine       Date:  2019-09-06       Impact factor: 3.633

2.  A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma.

Authors:  Hao Xie; Jun Yin; Manisha H Shah; Michael E Menefee; Keith C Bible; Diane Reidy-Lagunes; Madeleine A Kane; David I Quinn; David R Gandara; Charles Erlichman; Alex A Adjei
Journal:  Invest New Drugs       Date:  2019-06-06       Impact factor: 3.850

3.  Immunotherapy failure in adrenocortical cancer: where next?

Authors:  Deborah Cosentini; Salvatore Grisanti; Alberto Dalla Volta; Marta Laganà; Chiara Fiorentini; Paola Perotti; Sandra Sigala; Alfredo Berruti
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335

4.  Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.

Authors:  Fangshi Xu; Yibing Guan; Yubo Ma; Li Xue; Peng Zhang; Xiaojie Yang; Tie Chong
Journal:  Aging (Albany NY)       Date:  2021-04-21       Impact factor: 5.682

Review 5.  Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma.

Authors:  Chiara Fiorentini; Salvatore Grisanti; Deborah Cosentini; Andrea Abate; Elisa Rossini; Alfredo Berruti; Sandra Sigala
Journal:  J Oncol       Date:  2019-04-01       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.